Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Bob Abraham

Executive Vice President and Head of Cancer Biology

David Pompliano

Co-Founder and Chief Innovation Officer

1 past transactions

Rahko

Acquisition in 2021

Rahko Limited is a company specializing in quantum machine learning (QML) software for chemical simulation, headquartered in London, United Kingdom. Founded in 2018, Rahko develops a platform that offers advanced QML algorithms and tools to enhance accessibility to quantum computers. The platform is designed to address significant challenges in chemical simulations relevant to batteries, chemicals, materials, and pharmaceuticals. By collaborating with major quantum hardware manufacturers and large corporations, Rahko aims to solve practical, commercially valuable problems within the realm of quantum chemistry. Their team consists of experts in various fields, including quantum software engineering and quantum chemistry, enabling them to make substantial progress in unlocking the potential of quantum technologies for scientific and industrial applications.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.